nocturnal oxygen therapy
Recently Published Documents


TOTAL DOCUMENTS

51
(FIVE YEARS 3)

H-INDEX

14
(FIVE YEARS 0)

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sophia Gutweniger ◽  
Tsogyal D. Latshang ◽  
Sayaka S. Aeschbacher ◽  
Fabienne Huber ◽  
Deborah Flueck ◽  
...  

AbstractThis trial evaluates whether nocturnal oxygen therapy (NOT) during a stay at 2048 m improves altitude-induced exercise intolerance in lowlanders with chronic obstructive pulmonary disease (COPD). 32 lowlanders with moderate to severe COPD, mean ± SD forced expiratory volume in the first second of expiration (FEV1) 54 ± 13% predicted, stayed for 2 days at 2048 m twice, once with NOT, once with placebo according to a randomized, crossover trial with a 2-week washout period at < 800 m in-between. Semi-supine, constant-load cycle exercise to exhaustion at 60% of maximal work-rate was performed at 490 m and after the first night at 2048 m. Endurance time was the primary outcome. Additional outcomes were cerebral tissue oxygenation (CTO), arterial blood gases and breath-by-breath measurements (http://www.ClinicalTrials.gov NCT02150590). Mean ± SE endurance time at 490 m was 602 ± 65 s, at 2048 m after placebo 345 ± 62 s and at 2048 m after NOT 293 ± 60 s, respectively (P < 0.001 vs. 490 m). Mean difference (95%CI) NOT versus placebo was − 52 s (− 174 to 70), P = 0.401. End-exercise pulse oximetry (SpO2), CTO and minute ventilation ($${\dot{\text{V}}}_{{\text{E}}}$$ V ˙ E ) at 490 m were: SpO2 92 ± 1%, CTO 65 ± 1%, $${\dot{\text{V}}}_{{\text{E}}}$$ V ˙ E 37.7 ± 2.0 L/min; at 2048 m with placebo: SpO2 85 ± 1%, CTO 61 ± 1%, $${\dot{\text{V}}}_{{\text{E}}}$$ V ˙ E  40.6 ± 2.0 L/min and with NOT: SpO2 84 ± 1%; CTO 61 ± 1%; $${\dot{\text{V}}}_{{\text{E}}}$$ V ˙ E  40.6 ± 2.0 L/min (P < 0.05, SpO2, CTO at 2048 m with placebo vs. 490 m; P = NS, NOT vs. placebo). Altitude-related hypoxemia and cerebral hypoxia impaired exercise endurance in patients with moderate to severe COPD and were not prevented by NOT.


Author(s):  
Mona Lichtblau ◽  
Tsogyal Latshang ◽  
Sayaka Aeschbacher ◽  
Fabienne Huber ◽  
Philipp Schweiwiller ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Maya Bisang ◽  
Tsogyal D. Latshang ◽  
Sayaka S. Aeschbacher ◽  
Fabienne Huber ◽  
Deborah Flueck ◽  
...  

Background: Chronic obstructive pulmonary disease (COPD) is associated with cardiovascular disease. We investigated whether sleeping at altitude increases nocturnal heart rate (HR) and other markers of cardiovascular risk or arrhythmias in lowlanders with COPD and whether this can be prevented by nocturnal oxygen therapy (NOT).Methods: Twenty-four COPD patients, with median age of 66 years and forced expiratory volume in 1 s (FEV1) 55% predicted, living &lt;800 m underwent sleep studies at Zurich (490 m) and during 2 sojourns of 2 days each at St. Moritz (2,048 m) separated by 2-week washout at &lt;800 m. During nights at 2,048 m, patients received either NOT (2,048 m NOT) or ambient air (2,048 m placebo) 3 L/min via nasal cannula according to a randomized, placebo-controlled crossover trial. Sleep studies comprised ECG and pulse oximetry to measure HR, rhythm, HR-adjusted QT interval (QTc), and mean oxygen saturation (SpO2).Results: In the first nights at 490 m, 2,048 m placebo, and 2,048 m NOT, medians (quartiles) of SpO2 were 92% (90; 94), 86% (83; 89), and 97% (95; 98) and of HR were 73 (66; 82), 82 (71; 85), and 78 bpm (67; 74) (P &lt; 0.05 all respective comparisons). QTc increased from 417 ms (404; 439) at 490 m to 426 ms (405; 440) at 2,048 m placebo (P &lt; 0.05) and was 420 ms (405; 440) at 2,048 m NOT (P = NS vs. 2,048 m placebo). The number of extrabeats and complex arrhythmias was similar over all conditions.Conclusions: While staying at 2,048 m, lowlanders with COPD experienced nocturnal hypoxemia in association with an increased HR and prolongation of the QTc interval. NOT significantly improved SpO2 and lowered HR, without changing QTc. Whether oxygen therapy would reduce HR and arrhythmia during longer altitude sojourns remains to be elucidated.


Author(s):  
Sophia Gutweniger ◽  
Tsogyal D. Latshang ◽  
Sayaka S. Aeschbacher ◽  
Fabienne Huber ◽  
Deborah Flueck ◽  
...  

2020 ◽  
Vol 7 ◽  
Author(s):  
Mona Lichtblau ◽  
Stéphanie Saxer ◽  
Tsogyal D. Latshang ◽  
Sayaka S. Aeschbacher ◽  
Fabienne Huber ◽  
...  

2020 ◽  
Vol 98 ◽  
pp. 176-179
Author(s):  
Chongxing Shen ◽  
Xiaofeng Yue ◽  
Jianwu Wang ◽  
Chunmeng Shi ◽  
Weibing Li

CHEST Journal ◽  
2017 ◽  
Vol 151 (5) ◽  
pp. A54
Author(s):  
M. Bisang ◽  
T.D. Latshang ◽  
M. Furian ◽  
S.S. Aeschbacher ◽  
F. Huber ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document